Year: 2022

news_6

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors

SHANGHAI & SUZHOU, China & GERMANTOWN, Md.--(BUSINESS WIRE)--Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company dedicated to discovering and...

news_6

Capstone Achieves Upper End of 2021 Production Guidance and Provides 2022 Guidance for Pinto Valley, Cozamin, and Santo Domingo

(All amounts in US$ unless otherwise specified) VANCOUVER, British Columbia--(BUSINESS WIRE)--#CapstoneCopper--Capstone Mining Corp. (“Capstone” or the “Company”) (TSX:CS) is pleased...